- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04444349
Effects of CoQ10 on Inflammatory Response in Cardiac Surgery
June 22, 2020 updated by: Hong Liu, Nanjing Medical University
The Effects of the Dietary Supplement Coenzyme Q10 on Inflammatory Responses in Individuals With Cardiac Surgery: A Randomized Controlled Trial
Cardiovascular diseases are the leading causes of death and prescription drug use.
Research on certain dietary supplements looks promising as a way to help reduce risk factors.
Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed.
The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult men and women
- Elective cardiac surgery
- Cardiac surgery on cardiopulmonary bypass
Exclusion Criteria:
- Pregnant or planning on getting pregnant during the study
- Emergency cardiac surgery
- Contain a minimum of 2 traits of metabolic syndrome
- Cardiac surgery without cardiopulmonary bypass
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Coenzyme Q10 group
Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
|
Coenzyme Q10 is a cardiovascular health supplement.
It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP.
The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
Other Names:
|
Sham Comparator: Control
Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
|
placebo that looks and tastes identical to Coenzyme Q10
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-reactive protein
Time Frame: Change from baseline of CRP in mg/L at 5 days after surgery.
|
Inflammatory and endothelial blood work biomarkers
|
Change from baseline of CRP in mg/L at 5 days after surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interleukin-6
Time Frame: Change from baseline of IL-6 in pg/mL at 5 days after surgery.
|
Inflammatory and endothelial blood work biomarkers
|
Change from baseline of IL-6 in pg/mL at 5 days after surgery.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2020
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
June 20, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 23, 2020
Study Record Updates
Last Update Posted (Actual)
June 23, 2020
Last Update Submitted That Met QC Criteria
June 22, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CoQ10-Jph 2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
-
Penn State UniversityCalifornia Walnut CommissionCompletedCardiovascular DiseaseUnited States
Clinical Trials on Coenzyme Q10
-
University of SumerCompletedMale InfertilityIraq
-
University of ShizuokaCompletedHemodialysis | Chronic Renal FailureJapan
-
Central Hospital, Nancy, FranceCompletedCyclic Vomiting SyndromeFrance
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedAmyotrophic Lateral Sclerosis | Lou Gehrig's DiseaseUnited States
-
Hadassah Medical OrganizationUnknown
-
Peter HumaidanCompleted
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedHuntington's DiseaseUnited States
-
Technische Universität DresdenDeutsche Parkinson-Vereinigung e.V.; MSE Pharmazeutika GmbH, Bad HomburgCompleted
-
Mclean HospitalNational Alliance for Research on Schizophrenia and DepressionCompleted
-
National University Hospital, SingaporeCompletedParkinson DiseaseSingapore